St. Jude Medical Inc. lands European regulatory approval for a cardiac ablation system used to correct arrhythmias.
St. Jude Medical Inc. (NYSE:STJ) received European regulatory approval for a cardiac ablation system used in procedures to destroy diseased tissue in patients with abnormal heart rhythms.
Receiving the CE Mark means that St. Jude may beginning marketing and selling its EnSite Contact Technology platform in the Eurpean Union. The system has not been cleared for U.S. sales.
Medtronic's cardiac and vascular group president, Michael Coyle, questions CardioMEMS' implantable...
Scott Davis Joins Resonetics as New Director of Quality Assurance and Regulatory Affairs
ResMed says it acquired Czech distributor Unimedis for an undisclosed amount.
The U.S. Food & Drug Administration releases a list of pre-market approvals granted in August...